Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alternative Splicing | 6 | 2023 | 201 | 2.030 |
Why?
|
| Genes, BRCA2 | 7 | 2016 | 160 | 1.370 |
Why?
|
| BRCA2 Protein | 7 | 2016 | 158 | 1.180 |
Why?
|
| Genes, BRCA1 | 10 | 2016 | 192 | 1.060 |
Why?
|
| Breast Neoplasms | 21 | 2016 | 2903 | 0.990 |
Why?
|
| BRCA1 Protein | 10 | 2016 | 200 | 0.960 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2016 | 2271 | 0.740 |
Why?
|
| Mutation | 12 | 2023 | 3968 | 0.690 |
Why?
|
| RNA, Messenger | 9 | 2023 | 1981 | 0.670 |
Why?
|
| Exons | 4 | 2012 | 450 | 0.610 |
Why?
|
| RNA Splicing | 2 | 2023 | 142 | 0.500 |
Why?
|
| Introns | 4 | 2012 | 289 | 0.450 |
Why?
|
| Neoplasms | 3 | 2023 | 2898 | 0.430 |
Why?
|
| Germ-Line Mutation | 4 | 2016 | 329 | 0.430 |
Why?
|
| Breast Neoplasms, Male | 4 | 2010 | 30 | 0.410 |
Why?
|
| Genetic Testing | 7 | 2016 | 535 | 0.410 |
Why?
|
| Alleles | 4 | 2007 | 1128 | 0.410 |
Why?
|
| Ovarian Neoplasms | 5 | 2016 | 744 | 0.330 |
Why?
|
| Nigeria | 7 | 2013 | 152 | 0.280 |
Why?
|
| Tubulin | 3 | 1997 | 58 | 0.280 |
Why?
|
| Microtubules | 3 | 1997 | 119 | 0.270 |
Why?
|
| Drosophila melanogaster | 4 | 1997 | 599 | 0.240 |
Why?
|
| Female | 28 | 2016 | 44532 | 0.210 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2001 | 10 | 0.200 |
Why?
|
| RNA Splice Sites | 2 | 2016 | 53 | 0.190 |
Why?
|
| Mutation, Missense | 1 | 2002 | 276 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 51 | 0.190 |
Why?
|
| Humans | 32 | 2023 | 86643 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2000 | 18 | 0.190 |
Why?
|
| Oncogenes | 1 | 2000 | 88 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 279 | 0.170 |
Why?
|
| Prevalence | 3 | 2014 | 1239 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 2 | 2010 | 144 | 0.160 |
Why?
|
| Molecular Sequence Data | 8 | 2012 | 3030 | 0.150 |
Why?
|
| Carcinoma | 1 | 2000 | 436 | 0.140 |
Why?
|
| Base Sequence | 6 | 2012 | 2330 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2016 | 2767 | 0.140 |
Why?
|
| Pedigree | 5 | 2016 | 966 | 0.140 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 106 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2007 | 165 | 0.140 |
Why?
|
| Sperm Tail | 1 | 1995 | 2 | 0.130 |
Why?
|
| DNA Mutational Analysis | 4 | 2012 | 526 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 40 | 0.130 |
Why?
|
| Flagella | 1 | 1995 | 25 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 879 | 0.120 |
Why?
|
| Middle Aged | 16 | 2016 | 25028 | 0.120 |
Why?
|
| Breast | 2 | 2014 | 288 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2014 | 150 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 28 | 0.120 |
Why?
|
| Receptors, Estrogen | 3 | 2014 | 384 | 0.120 |
Why?
|
| Neoplasm Proteins | 3 | 2000 | 532 | 0.110 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 10 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 137 | 0.110 |
Why?
|
| Parity | 2 | 2013 | 93 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2426 | 0.100 |
Why?
|
| Adult | 15 | 2016 | 25648 | 0.100 |
Why?
|
| Mutation Rate | 1 | 2012 | 48 | 0.100 |
Why?
|
| Cell Line | 1 | 2016 | 2468 | 0.100 |
Why?
|
| Male | 12 | 2012 | 40965 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 265 | 0.100 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 23 | 0.090 |
Why?
|
| Age Factors | 3 | 2016 | 1851 | 0.090 |
Why?
|
| Risk Factors | 5 | 2013 | 5417 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2010 | 46 | 0.090 |
Why?
|
| Mitosis | 1 | 2010 | 153 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 170 | 0.090 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Cell Division | 1 | 2010 | 696 | 0.080 |
Why?
|
| Systems Integration | 1 | 2008 | 35 | 0.080 |
Why?
|
| Database Management Systems | 1 | 2008 | 41 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2000 | 1565 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.080 |
Why?
|
| Genetics, Population | 2 | 2008 | 394 | 0.080 |
Why?
|
| Genes | 1 | 1988 | 305 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2008 | 109 | 0.080 |
Why?
|
| Information Storage and Retrieval | 1 | 2008 | 120 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 93 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 1988 | 646 | 0.080 |
Why?
|
| Survival Rate | 1 | 2012 | 1863 | 0.080 |
Why?
|
| Amino Acid Sequence | 5 | 2006 | 2062 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 388 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 128 | 0.080 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2010 | 276 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2008 | 91 | 0.080 |
Why?
|
| Age of Onset | 2 | 2014 | 310 | 0.070 |
Why?
|
| Prognosis | 2 | 2012 | 3679 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 2357 | 0.070 |
Why?
|
| Global Health | 1 | 2007 | 193 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2007 | 184 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2005 | 55 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2007 | 628 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 110 | 0.070 |
Why?
|
| Computational Biology | 1 | 2008 | 528 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 645 | 0.060 |
Why?
|
| Mammography | 2 | 2014 | 463 | 0.060 |
Why?
|
| Mephenytoin | 1 | 2003 | 2 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 14 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 381 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 44 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2003 | 74 | 0.060 |
Why?
|
| Genetic Counseling | 2 | 2003 | 100 | 0.060 |
Why?
|
| Risk | 2 | 2007 | 674 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 1621 | 0.050 |
Why?
|
| Aged | 7 | 2014 | 18415 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2000 | 677 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2008 | 1351 | 0.050 |
Why?
|
| Family Health | 1 | 2001 | 162 | 0.050 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2000 | 10 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2000 | 24 | 0.050 |
Why?
|
| Case Management | 1 | 2000 | 24 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2000 | 48 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2001 | 293 | 0.050 |
Why?
|
| Haplotypes | 3 | 2008 | 642 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2006 | 408 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2000 | 83 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2000 | 81 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2000 | 70 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 100 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2000 | 168 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2000 | 329 | 0.040 |
Why?
|
| Premenopause | 2 | 2013 | 54 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 1230 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 937 | 0.040 |
Why?
|
| Mastectomy | 1 | 2000 | 243 | 0.040 |
Why?
|
| Spermatogenesis | 2 | 1997 | 37 | 0.040 |
Why?
|
| Spermatids | 1 | 1997 | 5 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 927 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1805 | 0.040 |
Why?
|
| Logistic Models | 2 | 2013 | 1186 | 0.030 |
Why?
|
| Founder Effect | 2 | 2008 | 104 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 782 | 0.030 |
Why?
|
| Genotype | 2 | 2012 | 1851 | 0.030 |
Why?
|
| DNA | 1 | 2001 | 1294 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1995 | 97 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 20 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1995 | 290 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1995 | 210 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 204 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 190 | 0.030 |
Why?
|
| Geography | 1 | 2014 | 223 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 167 | 0.030 |
Why?
|
| Phenotype | 1 | 2000 | 2378 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 2894 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 270 | 0.030 |
Why?
|
| Barbados | 1 | 2012 | 7 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2013 | 135 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 217 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 819 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 853 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 456 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 702 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 15 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
| Animals | 4 | 1997 | 26582 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2010 | 43 | 0.020 |
Why?
|
| RNA, Fungal | 1 | 2010 | 42 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 125 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1577 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 770 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2010 | 205 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 316 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 1988 | 40 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2010 | 250 | 0.020 |
Why?
|
| Embryonic and Fetal Development | 1 | 1988 | 72 | 0.020 |
Why?
|
| Genes, Lethal | 1 | 1988 | 53 | 0.020 |
Why?
|
| Oogenesis | 1 | 1988 | 45 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1988 | 157 | 0.020 |
Why?
|
| Online Systems | 1 | 2008 | 24 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1988 | 256 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 12 | 0.020 |
Why?
|
| Carcinoma, Medullary | 1 | 2008 | 11 | 0.020 |
Why?
|
| International Agencies | 1 | 2008 | 34 | 0.020 |
Why?
|
| United States | 2 | 2014 | 6672 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2008 | 43 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2008 | 145 | 0.020 |
Why?
|
| Plasmids | 1 | 1988 | 287 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 69 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
| Africa | 1 | 2007 | 98 | 0.020 |
Why?
|
| Models, Biological | 1 | 1995 | 1749 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1106 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 81 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2008 | 113 | 0.020 |
Why?
|
| CpG Islands | 1 | 2007 | 151 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2008 | 185 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 157 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 8489 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 49 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 416 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 6509 | 0.020 |
Why?
|
| Azacitidine | 1 | 2005 | 137 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2005 | 207 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2008 | 814 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 4213 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 355 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1384 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 236 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 736 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2003 | 6 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2003 | 11 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 50 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2003 | 49 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 1718 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 464 | 0.010 |
Why?
|
| Adolescent | 2 | 2008 | 8981 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 1098 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2261 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 1456 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 574 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2003 | 623 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1683 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 5976 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 319 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1284 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 1169 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 813 | 0.010 |
Why?
|
| Women's Health | 1 | 2000 | 100 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 3046 | 0.010 |
Why?
|
| Moths | 1 | 1997 | 31 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 3612 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 1997 | 181 | 0.010 |
Why?
|
| Child | 1 | 2003 | 6927 | 0.010 |
Why?
|